Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shares in EquiTech Corporation have risen almost 19%, after the company announced that its reformulated ibuprofen caplet was absorbed faster and demonstrated a potentially faster onset of action than a leading over-the-counter tablet.
Subscribe to our email newsletter
Data from a phase II clinical trial of ZAG-1701, EquiTech’s novel reformulated ibuprofen caplet, showed that ZAG-1701 is absorbed significantly faster and demonstrated a trend toward faster onset of action than McNeil Consumer & Specialty Pharmaceuticals’ Motrin IB.
The primary objective of the study was to compare the speed of absorption of ibuprofen into the bloodstream of a 400mg dose of ZAG-1701 with a 400mg dose of Motrin IB in patients experiencing the pain of wisdom tooth extraction, an accepted industry standard test. Previous work done by EquiTech scientists suggests that patients in pain may absorb drugs more slowly than healthy subjects.
The data from this clinical study showed that, at all measured time points from the time of drug administration to 1.5 hours later, the amount of the drug entering the blood stream was up to three-fold greater for ZAG-1701 compared to Motrin IB.
The data also showed that in patients who received ZAG-1701 caplets, peak concentrations of ibuprofen in the blood stream occurred on average at one hour and 26 minutes compared to two hours and 19 minutes for Motrin IB – over one and half times faster than Motrin IB.
The trial was not designed with sufficient statistical power to evaluate how patients rated their subjective sense of pain relief, however, using industry standard methods and questionnaires, patients taking ZAG-1701 reported a trend of faster pain relief compared to Motrin IB.
“We are extremely pleased with the results of this clinical study. The data supports our science and suggests that ZAG-1701 has the potential to provide rapid acting pain relief,” said James Chivers-Wilson, president and CEO of EquiTech. “The trial’s promising results will be confirmed in other clinical studies we are planning.”